Proteomic-driven precision medicine research in hepatocellular carcinoma.
10.3760/cma.j.cn501113-20220616-00328
- VernacularTitle:蛋白质组学驱动的肝细胞癌精准医学研究
- Author:
Ying JIANG
1
;
Fu Chu HE
1
Author Information
1. State Key Laboratory of Proteomics, National Center of Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China.
- Publication Type:Review
- MeSH:
Biomarkers;
Carcinoma, Hepatocellular/pathology*;
Humans;
Liver Neoplasms/pathology*;
Precision Medicine/methods*;
Proteomics/methods*
- From:
Chinese Journal of Hepatology
2022;30(8):797-802
- CountryChina
- Language:Chinese
-
Abstract:
Proteomics is the study of proteins-the direct executor of life activities. Protein plays a vital role in the development and growth of human body and the genesis and development of diseases. It is the most widely used clinical marker type and the direct drug target. In recent years, the advance of proteomic core technology with chromatography and mass spectrometry has promoted the rapid development in the depth and breadth of proteomic research, and its application in the large cohort of hepatocellular carcinoma opens a new era of proteomics-driven precision medicine (PDPM). This review highlights the proteomic research in new techniques, directions and discoveries of hepatocellular carcinoma research in recent years, providing new ideas and references for clinicians to understand proteomics, and to use proteomics to assist in the diagnosis of diseases and the development of personalized therapies.
